PDCD1 and neoplasm: Notably, the DHCR7 knockdown group combined with PD-1 inhibition (shDhcr7+PD-1) demonstrated more significant tumor growth suppression, with further reduced tumor volume and weight compared to the group with DHCR7 knockdown alone.